Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutical momentum and its own 64-year dividend streak intact.
Both are Dividend Kings built for uncertainty. But the businesses behind those credentials differ fundamentally, and that difference matters more than yield alone.
Zero Sugar Carries Coca-Cola. Oncology Carries Johnson & Johnson.
Coca-Cola’s Q4 story centered on Zero Sugar. Coca-Cola Zero Sugar unit case volume rose 13% in Q4 and 14% for the full year, giving CEO James Quincey evidence that the health-conscious pivot is working.
North America held up well, with comparable currency-neutral operating income rising 15% in Q4. New products including Simply Pop prebiotic soda, Powerade Power Water, and a U.S. cane sugar Coca-Cola variant expand the brand’s portfolio. A $960 million non-cash BODYARMOR trademark impairment dragged reported operating income down sharply, and Asia Pacific revenue fell 7% YoY.
Johnson & Johnson’s Q1 2026 was built on pharmaceutical firepower. DARZALEX generated $3.96 billion, up 22.5% YoY. TREMFYA surged 68.3% to $1.61 billion, and CARVYKTI, its cell therapy for multiple myeloma, rose 62.1% to $597 million.
MedTech contributed with cardiovascular revenue up 13.0% to $2.38 billion. CEO Joaquin Duato highlighted new approvals: “Our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe.”
| Business Driver | Coca-Cola | Johnson & Johnson |
|---|---|---|
| Main Growth Engine | Zero Sugar beverages, pricing discipline | Oncology drugs, MedTech cardiovascular |
| Key Headwind | BODYARMOR impairment, Asia Pacific volume | STELARA biosimilar erosion (~920 bps drag) |
| Revenue Scale | $47.94B full year 2025 | $94.19B full year 2025 |
| Market Cap | ~$324.1B | ~$574.9B |
One Sells Beverages Globally. One Replaces Blockbusters With Better Ones.
Coca-Cola’s strategy rests on pricing power, brand loyalty, and an asset-light refranchising model that keeps capital requirements modest. Full-year 2026 guidance calls for organic revenue growth of 4%-5% and comparable EPS growth of 7%-8% off a $3 base.
The Powerade FIFA World Cup 2026 activation provides a live marketing platform this year. Currency exposure remains a constraint: a 5-point currency headwind hit comparable EPS in 2025, and the company navigates volume softness in Mexico, Thailand, and India.
| Lens | Coca-Cola | Johnson & Johnson |
|---|---|---|
| Dividend Streak | 63 consecutive years | 64 consecutive years |
| Current Quarterly Dividend | $0.53 | $1.34 |
| YTD Price Performance | +8.46% | +15.94% |
| Trailing P/E | 25x | 22x |
Johnson & Johnson executes a harder transition. STELARA revenue fell 59.7% YoY to $656 million as biosimilar competition accelerated. The pipeline absorbs that pressure.
Full-year 2026 guidance was raised to revenue of $100.3B-$101.3B with adjusted EPS of $11.45-$11.65. A planned separation of the DePuy Synthes orthopaedics business adds execution risk but could sharpen focus on higher-growth segments.
The Next Test Is Whether Pipelines and Pricing Hold Together
For Coca-Cola, the question is whether Zero Sugar momentum expands globally while currency headwinds and regional volume softness stay contained. Simply Pop and cane sugar Coca-Cola are early-stage bets.
Free cash flow guidance of approximately $12.2 billion for 2026 suggests management confidence, but the BODYARMOR write-down reminds investors that brand extensions do not always pay off.
For Johnson & Johnson, the STELARA cliff is known and partially priced in. The real test is whether TREMFYA, CARVYKTI, and ICOTYDE sustain growth trajectories long enough to absorb lost revenue.
The December 2026 Enterprise Business Review will clarify how the orthopaedics separation fits the long-term plan.
Johnson & Johnson for Total Return, Coca-Cola for Stability
Both companies earned Dividend King status. Coca-Cola’s beta of 0.36 and steady consumer staples base make it a classic capital-preservation holding. Johnson & Johnson’s 15.94% YTD gain versus Coca-Cola’s 8.46% reflects the market’s preference for pipeline-driven growth.
Coca-Cola’s low-volatility profile and unbroken dividend history since 1963 reflect a business built for capital preservation. Johnson & Johnson’s pipeline transition and corporate restructuring carry more execution risk, but the revenue growth trajectory and longer dividend streak reflect a different kind of durability. The deeper pipeline may ultimately determine which streak proves more sustainable.
Top Gaining Stocks
Top Losing Stocks